

Scandinavian ChemoTech - Starting the year on the right foot

Redeye provides an update on Scandinavian ChemoTech following the strong Q1 2024 report. Net sales came in 77% above our estimates, at cSEK1.3m, and the cost control from the company was impressive. We increase our sales estimates, lower the cost base slightly, and increase our valuation.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Scandinavian ChemoTech - Starting the year on the right foot